FA
LKFT

FDx Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

FDx Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,247
Closed -$327K – 829
2021
Q1 		$327K Buy
4,247
+90
+2% +$8.29K 0.01% 597
2020
Q4 		$411K Buy
4,157
+863
+26% +$106K 0.02% 489
2020
Q3 		$467K Buy
3,294
+5
+0.2% +$834 0.02% 397
2020
Q2 		$649K Buy
3,289
+747
+29% +$155K 0.03% 291
2020
Q1 		$498K Sell
2,542
-405
-14% -$87.1K 0.03% 290
2019
Q4 		$610K Buy
2,947
+32
+1% +$5.92K 0.03% 310
2019
Q3 		$445K Buy
2,915
+761
+35% +$125K 0.03% 371
2019
Q2 		$278K Buy
2,154
+115
+6% +$13.6K 0.01% 662
2019
Q1 		$240K Buy
+2,039
New +$206K 0.01% 676

Other funds holding LKFT

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

FDx Advisors's LKFT Position: Q2 2021 in Review

FDx Advisors sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2021, closing a stake of 4,247 shares — an estimated $327K sold.

FDx Advisors first reported a position in LKFT in Q1 2019 and held it in 9 quarters. The position peaked at $649K in Q2 2020. 108 funds tracked by Wall St. Rank hold LKFT as of Q2 2021.

  • FDx Advisors reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2021 after selling out during the quarter.
  • FDx Advisors sold 4,247 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2021, an estimated $327K.
  • FDx Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2019 and held it in 9 quarters.
  • FDx Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $649K in Q2 2020.
  • 108 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2021.

Based on FDx Advisors's 13F filing for Q2 2021, filed 5 Aug 2021.